Abstract:BACKGROUND:This study is a retrospective evaluation of the efficacy of neoadjuvant chemotherapy (NC) with a vinorelbine (V) and epirubicin (E) intravenous combination regimen and is aimed at identification of predictive markers for the long-term outcome in noninflammatory locally advanced breast cancer (NLABC).METHODS:One-hundred-and-nineteen patients with NLABC were identified from September 2001 to May 2006. Analysis was performed in March 2008, with a median follow-up of 63.4 months (range, 9-76 months). All patients were diagnosed with invasive breast cancer using 14 G core needle biopsy and treated with three cycles of VE before surgery. Local-regional radiotherapy was offered to all patients after the completion of chemotherapy followed by hormonal therapy according to hormone receptor status. Tissue sections cut from formalin-fixed paraffin-embedded blocks from biopsy specimens and postoperative tumor tissues were stained for the presence of estrogen receptor (ER), progesterone receptor (PgR), HER-2 (human epidermal growth factor receptor-2), and MIB-1(Ki-67).RESULTS:Patients characteristics were median age 52 years (range: 25-70 years); clinical TNM stage, stage IIB (n = 32), stage IIIA (n = 56), stage IIIB (n = 22) and stage IIIC (n = 9). All patients were evaluable for response: clinically complete response was documented in 27 patients (22.7%); 78 (65.6%) obtained partial response; stable disease was observed in 13 (10.9%); 1 patient (0.8%) had progressive disease. Pathological complete response was found in 22 cases (18.5%). Seventy-five patients were alive with no recurrence after a median follow-up of 63.4 months, the 5-year rates for disease-free survival and overall survival were 58.7% and 71.3%, respectively, after the start of NC. On multivariate analysis, the independent variables associated with increased risk of relapse and death were high pre-Ki-67(p = 0.012, p = 0.017, respectively), high post-Ki-67 expression (p = 0.045, p = 0.001, respectively), and non-pCR (p = 0.034, p = 0.027, respectively). A significantly increased risk of death was associated with lack of pre-ER expression (p = 0.002). Among patients with non-pCR, those with a pathological response at the tumor site with special involvement (i.e. skin, vessel and more than one quadrant) were at a higher risk of disease relapse and death (p < 0.001, p = 0.001, respectively).CONCLUSION:This study suggests the promising use of a VE regimen as NC for Chinese NLABC after a median follow-up of 63.4 months. Pathological response in the tumor site, pre-Ki-67 and post-Ki-67 expression, and pre-ER expression were the important variables that predicted long-term outcome. Patients with pathological special involvement at the primary site after NC had the lowest survival rates.

Chemotherapy of NA and NP regimens in 48 patients with advanced breast cancer

Comparison of NP Regimen and TP Regimen in Treatment of Advanced Breast Cancer

A Clinical Study on Efficacy and Toxicity of NP in Contrast to the MNP Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

[Effects and Toxicity of Neoadjuvant Chemotherapy with Vinorelbine and Cisplatin in Treatment of Operable Breast Cancer Previously Non-Responsive to Anthracyclines and Taxanes-Containing Regimen: Analysis of 19 Cases].

A Comparative Study for Vinorelbine with Cisplatin Plus Mitomycin and Vinorelbine with Cisplatin in Advanced Non-Small-cell Lung Cancer

Comparison of Vinorelbine Plus Cisplatin with Vinorelbine Plus Capecitabine in Patients with Anthracyclines- and Taxanes-Refractory Advanced Breast Cancer*

[Efficacy and Toxicity of Vinorelbine (Nvb)-Based Regimens in Patients with Metastatic Triple Negative Breast Cancer (mtnbc) Pretreated with Anthracyclines and Taxanes].

Clinical Study of Different Regimens As Neoadjuvant Chemotherapy for Local Advanced Breast Cancer

Comparison of Short-term Efficacy between the NP and GP Regimens in the Treatment of Advanced Non-small-cell Lung Canaer

First-line regimen of Vinorelbine and Cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

[Effects of vinorelbine plus cisplatin as second-line neoadjuvant chemotherapy regimen in the treatment of breast cancer].

First-line chemotherapy of vinorelbine/cisplatin (NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer (NSCLC): P2-327

Clinical Observation of Chemotherapy with NP and GP Regimens on Advanced Non-Small Cell Lung Cancer Patients

Chemotherapy Based on Regimes of Gemcitabine Plus Cisplatin or Vinorelbine Plus Cisplatin in Patients with Advanced NSCLC

Compare and Evaluate Two Combination Regimens of Vinorelbine Plus Gemcitabine and Cisplatin Pins Vinorelbine for Treatment of Patients with Advanced Non-Small-cell Lung Cancer

The application of different chemotherapy regimens in non-small cell lung cancer

Comparison of Different Regimen in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Retrospective Analysis of 119 Chinese Noninflammatory Locally Advanced Breast Cancer Cases Treated with Intravenous Combination of Vinorelbine and Epirubicin As a Neoadjuvant Chemotherapy: a Median Follow-Up of 63.4 Months.

[A Study of the Combination of Vinorelbine and Epirubicin As Neoadjuvant Chemotherapy Regimen in the Treatment of Locally Advanced Breast Cancer].

Vinorelbine plus cisplatin in the treatment of 48 cases with advanced non-small-cell lung cancer